Paper Details

  1. Home
  2. Paper Details

Long-term effects of weight-reducing drugs in people with hypertension.

Author: BergholdAndrea, HorvathKarl, JeitlerKlaus, MeschikJutta, PoschNicole, SemlitschThomas, SiebenhoferAndrea

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

In adults with essential hypertension, orlistat and sibutramine reduced body weight to a similar degree, while phentermine/topiramate reduced body weight to a greater extent. Orlistat and phentermine/topiramate reduced blood pressure, while sibutramine increased it. Long-term trials investigating the effects of these drugs on mortality and morbidity are needed.
Paper Details　
Original Abstract of the Article :
BACKGROUND: All major guidelines on antihypertensive therapy recommend weight loss; anti-obesity drugs may be able to help in this respect. PRIMARY OBJECTIVES: To assess the long-term effects of pharmacologically induced reduction in body weight in adults with essential hypertension on all-cause mo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD007654.pub4

データ提供：米国国立医学図書館（NLM）

A Balancing Act of Health: Exploring the Long-Term Effects of Weight-Reducing Drugs in Hypertensive Patients

Imagine a desert landscape, where the journey to health requires navigating a delicate balance between sustenance and weight management. This research explores the use of weight-reducing drugs in patients with hypertension, examining their long-term effects on cardiovascular health, body weight, and overall well-being. The study delves into the potential benefits and risks of these medications, seeking to understand their impact on cardiovascular health and overall patient outcomes.

Weighing the Options: A Comprehensive Assessment of Weight-Reducing Drugs for Hypertensive Patients

The researchers conducted a systematic review of randomized controlled trials, examining the long-term effects of various weight-reducing drugs, including orlistat, sibutramine, and phentermine/topiramate, in patients with hypertension. The study found that these medications were generally effective in reducing body weight, but there were concerns about potential side effects, particularly gastrointestinal issues with orlistat and cardiovascular risks with sibutramine.

A Call for Caution: Navigating the Risks and Benefits of Weight-Reducing Drugs

This research serves as a reminder that even medications intended to improve health can have unintended consequences. The study highlights the importance of carefully considering the risks and benefits of weight-reducing drugs, particularly for individuals with hypertension. It emphasizes the need for long-term trials to assess the long-term impact of these medications on cardiovascular health and mortality.

Dr. Camel's Conclusion

This research underscores the importance of a holistic approach to managing hypertension, emphasizing the need to consider both lifestyle modifications and pharmacological interventions. It's a reminder that in the vast desert of medical knowledge, we must always be vigilant in evaluating the risks and benefits of our treatment options, ensuring that we are providing the safest and most effective care for our patients.

Date :
  1. Date Completed 2016-07-06
  2. Date Revised 2021-02-02
Further Info :

Pubmed ID

26934640

DOI: Digital Object Identifier

10.1002/14651858.CD007654.pub4

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.